Search
Alefacept
go.drugbank.com/drugs/DB00092ApprovedWithdrawnImmunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells,...
Delavirdine
go.drugbank.com/drugs/DB00705ApprovedInvestigationalWithdrawnA potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Synonyms: (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide), 2-(4-(5-methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamineEVT 201
go.drugbank.com/drugs/DB05721InvestigationalEVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
Naftifine
go.drugbank.com/drugs/DB00735ApprovedNaftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Tri...
MBT-0312
go.drugbank.com/drugs/DB05880ExperimentalMediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Talampanel
go.drugbank.com/drugs/DB04982InvestigationalTalampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.
ADX-10061
go.drugbank.com/drugs/DB05419ExperimentalADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
BACTEK-R
go.drugbank.com/drugs/DB16526InvestigationalMV130 contains different components of whole heat-inactivated gram-positive and -negative bacteria that are involved in upper and lower respiratory infections. … Though studies have shown that it reduces the rate of infections in recurrent respiratory tract infections (RRTIs), the complete mechanisms are not fully understood.
Tozorakimab
go.drugbank.com/drugs/DB16473InvestigationalTozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. … moderate-to-severe asthma), NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in
Cyclic GMP
go.drugbank.com/drugs/DB02315ExperimentalIts levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) … Cyclic guanosine monophosphate (Cyclic GMP) is a guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions.